Aflibercept Most Effective For Severe Diabetic Macular Edema In New Trial.

This research being conducted on the medications that have been approved to control diabetic macular edema and diabetic retinopathy.
By News Staff
Diabetes is a significant risk factor for developing eye diseases and the most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy, which is caused by elevated blood sugar levels damaging the blood vessels of the retina and affects approximately 7.7 million Americans. 
About 750,000 Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula,the area of the retina used when looking straight ahead. The fluid causes the macula to swell, blurring vision. 
In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss. One drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated. The trial was conducted by the National Eye Institute Diabetic Retinopathy Clinical Research Network. 
Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee and an ophthalmologist in at Joslin Research Center says that in an earlier study, they found that VEGF, a major growth factor for blood vessels, is elevated in the eye fluids of patients with proliferative diabetic retinopathy and DME, causing leakage and the growth of abnormal blood vessels. Over the past few years, drugs that target VEGF have become a standard treatment for DME, providing a preferred alternative or adjunct to laser treatment. The standard Medicare per-injection costs of the three anti-VEGF drugs evaluated in the study are about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin). 
So in severe cases, you get what you pay for.
At the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes. About half of the participants had 20/32 or 20/40 vision and the other half had vision of 20/50 or worse. They were randomized into three treatment groups and received the assigned study drug by injection into the eye until the DME resolved or stabilized. Participants on bevacizumab and ranibizumab received, on average, 10 injections, versus nine for those on aflibercept……..
Read More:
Source: Science 2.0